{"doc_id": "33577800", "type of study": "Therapy", "title": "", "abstract": "Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.\nCOVID-19 is associated with both venous and arterial thrombotic complications.\nWhile prophylactic anticoagulation is now widely recommended for hospitalized patients with COVID-19, the effectiveness and safety of thromboprophylaxis in outpatients with COVID-19 has not been established.\nSTUDY DESIGN : PREVENT-HD is a double-blind, placebo-controlled, pragmatic, event-driven phase 3 trial to evaluate the efficacy and safety of rivaroxaban in symptomatic outpatients with laboratory-confirmed COVID-19 at risk for thrombotic events, hospitalization, and death.\nSeveral challenges posed by the pandemic have necessitated innovative approaches to clinical trial design, start-up, and conduct.\nParticipants are randomized in a 1:1 ratio, stratified by time from COVID-19 confirmation, to either rivaroxaban 10 mg once daily or placebo for 35 days.\nThe primary efficacy end point is a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic embolization, all-cause hospitalization, and all-cause mortality.\nThe primary safety end point is fatal and critical site bleeding according to the International Society on Thrombosis and Haemostasis definition.\nEnrollment began in August 2020 and is expected to enroll approximately 4,000 participants to yield the required number of end point events.\nPREVENT-HD is a pragmatic trial evaluating the efficacy and safety of the direct oral anticoagulant rivaroxaban in the outpatient setting to reduce major venous and arterial thrombotic events, hospitalization, and mortality associated with COVID-19.\nCopyright \u00a9 2021 Elsevier Inc. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 120}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 134}, {"term": "symptomatic outpatients", "negation": "affirmed", "UMLS": {}, "start": 160, "end": 183}, {"term": "laboratory-confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 218}, {"term": "at risk for thrombotic events", "negation": "affirmed", "UMLS": {}, "start": 219, "end": 248}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Rationale and design for the study of rivaroxaban to reduce thrombotic events , hospitalization and death in outpatients with COVID-19 : The PREVENT-HD study .", "Evidence Elements": {"Participant": [{"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 120}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 134}], "Intervention": [{"term": "rivaroxaban", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 49}], "Outcome": [{"term": "thrombotic events", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 77}, {"term": "hospitalization", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 95}, {"term": "death", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 105}], "Observation": [{"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 59}], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "COVID-19 is associated with both venous and arterial thrombotic complications .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "While prophylactic anticoagulation is now widely recommended for hospitalized patients with COVID-19 , the effectiveness and safety of thromboprophylaxis in outpatients with COVID-19 has not been established .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "STUDY DESIGN : PREVENT-HD is a double-blind , placebo-controlled , pragmatic , event-driven phase 3 trial to evaluate the efficacy and safety of rivaroxaban in symptomatic outpatients with laboratory-confirmed COVID-19 at risk for thrombotic events , hospitalization , and death .", "Evidence Elements": {"Participant": [{"term": "symptomatic outpatients", "negation": "affirmed", "UMLS": {}, "start": 160, "end": 183}, {"term": "laboratory-confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 218}, {"term": "at risk for thrombotic events", "negation": "affirmed", "UMLS": {}, "start": 219, "end": 248}], "Intervention": [{"term": "rivaroxaban", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 156}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 122, "end": 130}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 135, "end": 141}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Several challenges posed by the pandemic have necessitated innovative approaches to clinical trial design , start-up , and conduct .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Participants are randomized in a 1:1 ratio , stratified by time from COVID-19 confirmation , to either rivaroxaban 10 mg once daily or placebo for 35 days .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "rivaroxaban", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 114}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 135, "end": 142}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary efficacy end point is a composite of symptomatic venous thromboembolism , myocardial infarction , ischemic stroke , acute limb ischemia , non-central nervous system systemic embolization , all-cause hospitalization , and all-cause mortality .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "composite of symptomatic venous thromboembolism", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 83}, {"term": "myocardial infarction", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 107}, {"term": "ischemic stroke", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 125}, {"term": "acute limb ischemia", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 147}, {"term": "non-central nervous system systemic embolization", "negation": "affirmed", "UMLS": {}, "start": 150, "end": 198}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary safety end point is fatal and critical site bleeding according to the International Society on Thrombosis and Haemostasis definition .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "fatal and critical site bleeding", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 64}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Enrollment began in August 2020 and is expected to enroll approximately 4,000 participants to yield the required number of end point events .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "PREVENT-HD is a pragmatic trial evaluating the efficacy and safety of the direct oral anticoagulant rivaroxaban in the outpatient setting to reduce major venous and arterial thrombotic events , hospitalization , and mortality associated with COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "direct oral anticoagulant rivaroxaban", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 111}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 55}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 66}, {"term": "major venous and arterial thrombotic events", "negation": "affirmed", "UMLS": {}, "start": 148, "end": 191}, {"term": "hospitalization", "negation": "affirmed", "UMLS": {}, "start": 194, "end": 209}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 216, "end": 225}], "Observation": [{"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 141, "end": 147}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Elsevier Inc . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}